Medical Condition News

RSS

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Ethicon Endo-Surgery today announced that the SEDASYS® System, the first computer-assisted personalized sedation (CAPS) system, was granted a CE Mark for the European Union for routine colonoscopy and screening of the upper gastrointestinal tract (EGD procedures), and Health Canada granted regulatory approval for the SEDASYS® System for use by healthcare professional teams during routine colonoscopy.

3 May 2010

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.

3 May 2010

Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery

Omeros Corporation today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy surgery achieved statistically significant clinical benefits.

3 May 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.

From Santen Pharmaceutical Co., Ltd. 3 May 2010

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.

3 May 2010

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

To coincide with Skin Cancer Awareness Month, the AVEENO Brand announces its third-year partnership with The Skin Cancer Foundation for the Road to Healthy Skin Tour, a program that has been instrumental in educating people nationwide about skin cancer detection and prevention. This year, the Tour will visit over 80 locations through September.

3 May 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).

3 May 2010

PolyTouch Medical files Premarket 510(k) application for PatchAssist laparoscopic mesh deployment device

PolyTouch Medical Ltd., a leading developer of laparoscopic hernia mesh placement technologies, today announced that it has filed a Premarket 510(k) Application with the US Food and Drug Administration for PatchAssist, an Innovative Laparoscopic Mesh Deployment and Placement Device that enables accurate mesh placement in laparoscopic ventral hernia repair potentially reducing procedure time by 30%-50%.

3 May 2010

African-Americans less likely to have varus thrust, more likely to have valgus thrust than Caucasians

A recent study determined that African-Americans were less likely to have a varus thrust, but more likely to have valgus thrust than Caucasians. Varus thrust is visualized during gait as the worsening or abrupt onset of varus (bow-legged) alignment as the leg accepts weight, with a return to less varus and more neutral alignment during lift-off of the foot and the swing phase of gait.

3 May 2010

Stimatix reports interim results from artificial sphincter trial for restoring bowel control in people with stoma

Stimatix GI, located in the Misgav Venture Accelerator, has reported encouraging interim results in its animal trials of the AOS-C1000 artificial sphincter, designed to provide stoma patients with a new means of bowel control.

3 May 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical Corp., announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans, LA on May 2, 2010.

3 May 2010

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

3 May 2010

Protein test to determine response of lung cancer patients to erlotinib

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

3 May 2010

New classification of depressive subtypes of depression proposed

Lichtenberg and Belmaker propose a new classification of depressive subtypes of depression in the current issue of Psychotherapy and Psychosomatics. They argue that a simple diagnosis is no longer sufficient to guide treatment.

3 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

Investigators examine effects of family-oriented interventions on adults with chronic physical diseases

In the current issue of Psychotherapy and Psychosomatics a group of German investigators examines the literature concerned with the effects of interventions involving the family in the treatment of patients with chronic disease.

3 May 2010

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis.

3 May 2010

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

Results of a new study found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) demonstrated significantly greater mean reductions at week 12 in blood pressure (37.1/21.8 mm Hg versus 27.5 to 30.0/15.1-18.0 mm Hg LS Mean Reductions, P< 0.0001), as compared to corresponding dual combination therapy (dual components).

3 May 2010

Pay-for-performance policies may create financial disincentives for doctors to treat obese patients

Pay-for-performance reimbursement of surgeons, intended to reward doctors and hospitals for good patient outcomes, may instead be creating financial incentives for discriminating against obese patients, who are much more likely to suffer expensive complications after even the most routine surgeries, according to new Johns Hopkins research.

3 May 2010

Study finds servicemen and women at increased risk for suicide

When young servicemen and women return home from a tour of duty, their family and friends breathe a sigh of relief, knowing their loved ones finally are safe and sound. New research, however, shows that is not always the case.

3 May 2010

Medical Condition News

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

PolyTouch Medical files Premarket 510(k) application for PatchAssist laparoscopic mesh deployment device

African-Americans less likely to have varus thrust, more likely to have valgus thrust than Caucasians

Stimatix reports interim results from artificial sphincter trial for restoring bowel control in people with stoma

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Protein test to determine response of lung cancer patients to erlotinib

New classification of depressive subtypes of depression proposed

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Investigators examine effects of family-oriented interventions on adults with chronic physical diseases

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

Pay-for-performance policies may create financial disincentives for doctors to treat obese patients

Study finds servicemen and women at increased risk for suicide

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News